JW Heparin Sodium Injection 1000 IU
Heparin Sodium
Injections · Prescription medication
JW Pharmaceutical Co., Ltd.
MFDS item code 198500112 · Notified 1985.02.01 · Insurance code 644903601,644914451
Prevention and treatment of thrombosis, embolism, and atrial fibrillation; diagnosis and treatment of coagulation disorders; inhibition of blood coagulation
This medication is used to prevent and treat thrombosis and pulmonary embolism. It also helps in the diagnosis and treatment of embolic atrial fibrillation and acute or chronic coagulopathies. It prevents blood clotting during and after surgery, reducing the occurrence of complications. It is effective in preventing cerebral thrombosis due to cerebral hemorrhage, and it prevents blood coagulation during transfusions, extracorporeal circulation, and dialysis. It is also used in treatment of acute myocardial infarction and peripheral vascular embolism. Overall, it improves prevention and treatment related to blood coagulation disorders.
Usually, administer by intravenous injection or add to the perfusate used during extracorporeal circulation. The effect occurs immediately after administration; however, heparin sensitivity varies considerably among individuals. Therefore, perform a heparin sensitivity test before administration, and after administration measure the blood coagulation time to determine the maintenance dose. Usually, maintain the blood coagulation time at 15 ~ 20 minutes or longer after use, but determine the dose according to the case, indication, and purpose. 1. Extracorporeal circulation 1) Artificial kidney (1) Systemic heparinization: Before starting dialysis, administer 1,000 ~ 5,000 IU of heparin sodium; after starting dialysis, continuously administer 500 ~ 1,500 IU per hour or intermittently administer an additional 500 ~ 1,500 IU every hour. (2) Regional heparinization: Continuously administer 1,500 ~ 2,500 IU of this drug per hour, and neutralize with protamine sulfate during extracorporeal perfusion. 2) Blood perfusion using a heart-lung machine : Administer 150 ~ 300 IU of this drug per kg of body weight, and add more as appropriate as the duration of extracorporeal circulation is extended. After extracorporeal circulation, use protamine sulfate to prevent postoperative bleeding and neutralize the effect of heparin. 2. Intravenous infusion Dissolve 10,000 ~ 30,000 IU of this drug in 1,000 mL of 5 % dextrose injection, normal saline injection, or Ringer's solution, and infuse at a rate of approximately 30 drops per minute. When the whole blood coagulation time reaches 2 ~ 3 times the pretreatment value, infuse at a rate of approximately 20 drops per minute. 3. Intermittent intravenous injection Administer 5,000 ~ 10,000 IU of this drug by intravenous injection every 4 ~ 8 hours. Starting 3 hours after initiation of administration, measure the whole blood coagulation time every 2 ~ 4 hours and adjust the dose to maintain it at 2 ~ 3 times the pretreatment value. 4. Subcutaneous injection Inject 10,000 ~ 20,000 IU of this drug subcutaneously, followed by a maintenance dose of 15,000 ~ 20,000 IU every 12 hours. Use a different injection site each time to prevent hematoma. 5. Blood transfusion and blood tests For blood transfusion, usually use 400 ~ 500 IU of this drug per 100 mL of blood; for blood tests, use 100 IU per 20 ~ 30 mL of blood.
This drug is a very potent medication and must only be used under strict medical supervision. Care must be taken when administering it to patients with a high risk of bleeding disorders, as it can cause bleeding from almost any part of the body. In some patients, fatal bleeding may occur, so caution is required. Additionally, the benzyl alcohol component in this medication can cause serious respiratory problems in premature infants, therefore it should not be used in neonates or premature babies. It should not be administered to patients who have had allergic reactions to this medication or its constituents, to patients with inappropriate coagulation test results, to patients who are bleeding or at high risk for bleeding, to those with severe liver or kidney disease, to patients who have recently had neurological or eye surgery, or those who have received spinal anesthesia or lumbar puncture. This drug regulates blood coagulation, so during treatment, regular blood coagulation tests and platelet counts should be checked, and administration should be discontinued immediately if there is a sudden decrease in platelet count. This medication should not be stopped abruptly, as there is a risk of thrombosis; the dosage should be gradually reduced. Also, when used in conjunction with this drug, especially with aspirin, non-steroidal anti-inflammatory drugs, or anticoagulants, the risk of bleeding may increase, so medical advice should be sought. Women who are pregnant or potentially pregnant should take special care due to the risk of uterine and placental bleeding, and those who are breastfeeding should also exercise caution due to the benzyl alcohol component. In elderly or pediatric patients, the risk of bleeding may also be higher, so it should be administered with caution. In case of overdose, the risk of bleeding increases, so it is important to promptly inform medical personnel; protamine sulfate can be used as an antidote, but this itself may have side effects, so caution is necessary. Avoid intramuscular injections during the administration of this drug, and do not mix it with other medications for injection. This medication must be used with great care, so it is very important to thoroughly follow medical instructions and undergo regular examinations before and after administration.
Hemorrhage, fatal hemorrhage, adrenal hemorrhage causing acute adrenal insufficiency, ovarian hemorrhage, retroperitoneal hemorrhage, gastrointestinal hemorrhage, cerebral hemorrhage, thrombocytopenia, arterial and venous thrombosis, acute reversible thrombocytopathy, elevated γ-GTP, elevated LDH, elevated AST, elevated ALT, pruritus, urticaria, chills, fever, rhinitis, bronchial asthma, tearing, conjunctivitis, cyanosis, tachycardia, feeling of pressure, vascular neurogenic edema, nausea, vomiting, hypotension, dyspnea, bronchospasm, shock, hair loss, vitiligo, hemorrhagic necrosis, hypoaldosteronism, osteoporosis, rebound effect, dyslipidemia, renal function suppression, localized painful hematoma, priapism, diabetes, hyperkalemia, hyperalkalemia, metabolic acidosis, elevated lipase, vascular spastic reaction, erythema, mild pain, ulcer
Not everyone experiences these, and they can vary from person to person.
This medication is sensitive to light and should be stored in opaque containers. It must also be kept sealed to prevent air exposure in order to maintain its efficacy over time.
A transparent liquid that is colorless to light yellow, housed in a brown glass vial.
5 mL x 10 vials, 20 mL x 10 vials
Even with the same ingredient, strength, dosage form and how it is taken can differ.
Heparin Sodium
Injections · Prescription medication
JW Pharmaceutical Co., Ltd.
Heparin Sodium
Injections · Prescription medication
JW Pharmaceutical Corporation
Heparin Sodium
Prescription medication
Hallym Pharmaceutical Co., Ltd.
Heparin Sodium
Prescription medication
Huons Co., Ltd.
Heparin Sodium
Prescription medication
Huons Co., Ltd.
Heparin Sodium
Injections · Prescription medication
Green Cross Corporation
Heparin Sodium
Prescription medication
Hyun's Co., Ltd.
Heparin Sodium
Prescription medication
BM Co., Ltd.
Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.
No questions yet.
For anything that needs medical judgment, consult a doctor or pharmacist.
This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.